Precipio appoints Board member Dick Sandberg as new Chairman of its Board of Directors

– USA, CT –  Precipio, Inc. (NASDAQ: PRPO), the specialty cancer diagnostics company today announced the appointment of Richard Sandberg as Chairman of the Board of Directors succeeding Dr. Douglas Fisher who will step down as Chairman but remain as a member of the board.

“I have been fortunate to have Dick Sandberg in my corner throughout the years as the company navigated the challenges of developing its business model and executing on its vision, and his counsel has been invaluable to myself and my team”, said CEO, Ilan Danieli. “I am honored to have Dick assume the role as chairman of the board and continue to be a driving force within the company’s leadership.”

Dr. Douglas Fisher joined the board in 2017 and assumed the role of Chairman in December 2019. During those years and under Doug’s leadership, the company completed the transition following its merger with Transgenomic; erased past liabilities, and has developed a business model that combines diagnostic services and products that have already begun to significantly impact the company’s value. Doug will continue to play a significant role as a director and will remain a contributing member of the board.

“I’m so pleased that Dick has agreed to be Chairman. It has been a pleasure to work with him as an independent director. His experience in the field uniquely qualifies him for this role, and I’m glad he is ready to step into it,” said Doug Fisher.

About Richard Sandberg

Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans.

Mr. Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the founder, chairman, CEO and CFO of Dianon Systems, Inc., a diagnostics company that was acquired in 2002 by LabCorp for $650M, Mr. Sandberg has direct experience relevant to Precipio’s business, the industry, and the challenges a growth company faces. Mr. Sandberg also serves as a director of Poplar Healthcare, LLC, a privately owned anatomical pathology laboratory with which the Company entered into a joint venture in 2020.

From 2008 to 2019, Mr. Sandberg also served as Chairman of the Board of Oxford Immunotec, which is being acquired by Perkin Elmer for over $550M, Mr. Sandberg also serves as Chief Executive Officer of Resolys Bio, Inc, a pharmaceutical company which is developing a treatment for long-term, chronic traumatic brain injury.

“Precipio is capitalizing on a unique opportunity to develop better diagnostic technology in support of its university-based pathology partnerships and to bring that technology to physician offices in the US and abroad. I am pleased and fortunate to have the chance to contribute to a company with so many opportunities to grow,” said Mr. Sandberg.

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

For more information : https://www.precipiodx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team